Hemedex, Inc.

Hemedex, Inc., was founded in 2000 to commercialize a proprietary platform technology conceived at the Massachusetts Institute of Technology to quantify tissue perfusion (i.e., blood flow at the capillary level). This technology addresses the need for real-time prognostic data in complex medical and surgical procedures. These complex procedures often involve compromised vasculature, delayed ischemia, or other serious pathophysiology, resulting in high rates of morbidity, delayed recuperation, poor patient outcome, and higher overall costs. Hemedex’s patented technology can provide an early warning of impending tissue ischemia, help target appropriate therapies, and rapidly assess the effect of interventions on cerebral blood flow (CBF), thus providing clinicians with a powerful tool to enhance patient care. All Hemedex products are FDA cleared. The Cranial Bolt Kit product line and the QFlow 500 Perfusion Probe are CE Marked.